Skip to content

Study · Observational study · 2026

18 results

Real-world persistence and dose titration of GLP-1 receptor agonists in type 2 diabetes: A UK population-based cohort study by obesity and cardiovascular disease status.

Ulrich FS, Napoli N, Nielsen MF, Burden AM

Diabetes, obesity & metabolism17 Feb 2026Cited by 5 (Europe PMC)

PMID41703773 (opens in a new tab)PMCIDPMC12992168 (opens in a new tab)DOI10.1111/dom.70535 (opens in a new tab)PepBankPUB-41703773
Download PDFPubMedAsk about this study
Jump to 18 results

Summary

AimsReal-world medication use varies across clinical trial and healthcare settings; therefore, we evaluated GLP-1 receptor agonist (GLP-1RA) persistence and dose titration among adults with type 2 diabetes in UK primary care, stratified by agent, obesity status, cardiovascular disease (CVD) history, and sex assigned at birth.Materials and methodsAdults with type 2 diabetes initiating GLP-1RAs between 1 March 2018 and 30 June 2023, with follow-up ≥1-year, were identified using the IQVIA Medical Research Data (IMRD) incorporating data from THIN, A Cegedim Database. The absolute 1-year risk of discontinuation was estimated using the Aalen-Johansen estimator, while multivariable cause-specific Cox models assessed associations with patient characteristics. Dosing trajectories were characterised across individual prescriptions during the first therapy year.ResultsAmong 8200 GLP-1RA initiators (46.5% dulaglutide, 38.7% semaglutide), the 1-year discontinuation risk was 41.1% (95% CI 40.1-42.2), higher among those without obesity (BMI 2: 49.2%, 46.5-52.0) versus with BMI ≥30 kg/m2 (BMI 30-2: 40.4%/37.2%, 38.4-42.4/35.4-39.1). Discontinuation was lower with dulaglutide (36.9%, 35.4-38.4) than with subcutaneous/oral semaglutide (46.4%/55.8%, 44.4-48.4/52.3-59.4). Only 58% of subcutaneous/oral semaglutide initiators reached recommended maintenance doses after 4 weeks, while 21% remained on starting doses. At prescription 10, most common doses were 0.5/1 mg subcutaneous semaglutide (44.0%/48.6%), 7/14 mg oral semaglutide (50.2%/36.6%), and 0.75/1.5/3 mg dulaglutide (20.4%/71.5%/6.7%). Faster dose escalation occurred with higher BMI and subcutaneous semaglutide (1 mg at prescription 5: 20.8%/25.9%/33.2% with BMI 2). Additional analyses (e.g., by CVD history) revealed no further heterogeneity.ConclusionsIn UK primary care, GLP-1RA persistence was suboptimal and dose escalation was frequently delayed across all patient stratifications, including individuals with established CVD.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study18

14 results from studies that gave the peptide. 14 results from people.

  1. 01HumanObservational studyOther

    In adults with T2DM, dulaglutide discontinuation risk was lower than with subcutaneous semaglutide.

    In plain wordsIn adults with diabetes, dulaglutide use was linked to less discontinuation than injected semaglutide.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseDiscontinuation versus subcutaneous semaglutide
    Study

    n: not reported in source

    Comparator
    Subcutaneous semaglutide
    Outcome group
    Treatment adherence and retention · Pharmacology
    Studied dose
    Dose not stated · 1 yearAs given in this study (human).

    Measurements

    Discontinuation risk
    36.9%
    dulaglutide
    Discontinuation risk
    46.4%
    subcutaneous semaglutide

    Source sentences

    Summary
    Discontinuation was lower with dulaglutide (36.9%, 35.4-38.4) than with subcutaneous/oral semaglutide (46.4%/55.8%, 44.4-48.4/52.3-59.4).
    3 context sentences
    Summary · context
    Adults with type 2 diabetes initiating GLP-1RAs between 1 March 2018 and 30 June 2023, with follow-up ≥1-year, were identified using the IQVIA Medical Research Data (IMRD) incorporating data from THIN, A Cegedim Database.
    Summary · context
    The absolute 1-year risk of discontinuation was estimated using the Aalen-Johansen estimator, while multivariable cause-specific Cox models assessed associations with patient characteristics.
    Summary · context
    Dosing trajectories were characterised across individual prescriptions during the first therapy year.
  2. 02HumanObservational studyOther

    In adults with T2DM, dulaglutide discontinuation risk was lower than with oral semaglutide.

    In plain wordsIn adults with diabetes, dulaglutide use was linked to less discontinuation than oral semaglutide.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseDiscontinuation versus oral semaglutide
    Study

    n: not reported in source

    Comparator
    Oral semaglutide
    Outcome group
    Treatment adherence and retention · Pharmacology
    Studied dose
    Dose not stated · 1 yearAs given in this study (human).

    Measurements

    Discontinuation risk
    36.9%
    dulaglutide
    Discontinuation risk
    55.8%
    oral semaglutide

    Source sentences

    Summary
    Discontinuation was lower with dulaglutide (36.9%, 35.4-38.4) than with subcutaneous/oral semaglutide (46.4%/55.8%, 44.4-48.4/52.3-59.4).
    3 context sentences
    Summary · context
    Adults with type 2 diabetes initiating GLP-1RAs between 1 March 2018 and 30 June 2023, with follow-up ≥1-year, were identified using the IQVIA Medical Research Data (IMRD) incorporating data from THIN, A Cegedim Database.
    Summary · context
    The absolute 1-year risk of discontinuation was estimated using the Aalen-Johansen estimator, while multivariable cause-specific Cox models assessed associations with patient characteristics.
    Summary · context
    Dosing trajectories were characterised across individual prescriptions during the first therapy year.
  3. 03HumanObservational studyOther

    In adults with T2DM, subcutaneous semaglutide discontinuation risk was higher than with dulaglutide.

    In plain wordsIn adults with diabetes, injected semaglutide use was linked to more discontinuation than dulaglutide.

    Peptide
    Semaglutide
    Outcome
    IncreaseSubcutaneous semaglutide discontinuation
    Study

    n: not reported in source

    Comparator
    Dulaglutide
    Outcome group
    Treatment adherence and retention · Pharmacology
    Studied dose
    Dose not stated · subcutaneous · 1 yearAs given in this study (human).

    Measurements

    Discontinuation risk
    46.4%
    subcutaneous semaglutide
    95% CI lower
    44.4%
    subcutaneous semaglutide
    95% CI upper
    48.4%
    subcutaneous semaglutide
    Discontinuation risk
    36.9%
    dulaglutide (comparator)

    Source sentences

    Summary
    Discontinuation was lower with dulaglutide (36.9%, 35.4-38.4) than with subcutaneous/oral semaglutide (46.4%/55.8%, 44.4-48.4/52.3-59.4).
    3 context sentences
    Summary · context
    Adults with type 2 diabetes initiating GLP-1RAs between 1 March 2018 and 30 June 2023, with follow-up ≥1-year, were identified using the IQVIA Medical Research Data (IMRD) incorporating data from THIN, A Cegedim Database.
    Summary · context
    The absolute 1-year risk of discontinuation was estimated using the Aalen-Johansen estimator, while multivariable cause-specific Cox models assessed associations with patient characteristics.
    Summary · context
    Dosing trajectories were characterised across individual prescriptions during the first therapy year.
  4. 04HumanObservational studyOther

    In adults with T2DM, oral semaglutide discontinuation risk was higher than with dulaglutide.

    In plain wordsIn adults with diabetes, oral semaglutide use was linked to more discontinuation than dulaglutide.

    Peptide
    Semaglutide
    Outcome
    IncreaseOral semaglutide discontinuation
    Study

    n: not reported in source

    Comparator
    Dulaglutide
    Outcome group
    Treatment adherence and retention · Pharmacology
    Studied dose
    Dose not stated · oral · 1 yearAs given in this study (human).

    Measurements

    Discontinuation risk
    55.8%
    oral semaglutide
    95% CI lower
    52.3%
    oral semaglutide
    95% CI upper
    59.4%
    oral semaglutide
    Discontinuation risk
    36.9%
    dulaglutide (comparator)

    Source sentences

    Summary
    Discontinuation was lower with dulaglutide (36.9%, 35.4-38.4) than with subcutaneous/oral semaglutide (46.4%/55.8%, 44.4-48.4/52.3-59.4).
    3 context sentences
    Summary · context
    Adults with type 2 diabetes initiating GLP-1RAs between 1 March 2018 and 30 June 2023, with follow-up ≥1-year, were identified using the IQVIA Medical Research Data (IMRD) incorporating data from THIN, A Cegedim Database.
    Summary · context
    The absolute 1-year risk of discontinuation was estimated using the Aalen-Johansen estimator, while multivariable cause-specific Cox models assessed associations with patient characteristics.
    Summary · context
    Dosing trajectories were characterised across individual prescriptions during the first therapy year.
  5. 05HumanObservational studyOther

    Among subcutaneous/oral semaglutide initiators with T2DM, only 58% reached recommended maintenance doses after 4 weeks.

    In plain wordsAmong semaglutide users with diabetes, only 58% reached recommended maintenance doses after 4 weeks.

    Peptide
    Semaglutide
    Outcome
    Not applicableMaintenance dose attainment
    Study

    n: not reported in source

    Outcome group
    Treatment adherence and retention · Pharmacology
    Studied dose
    Dose not stated · 4 weeksAs given in this study (human).

    Measurements

    Maintenance dose attainment
    58%
    subcutaneous/oral semaglutide

    Source sentences

    Summary
    Only 58% of subcutaneous/oral semaglutide initiators reached recommended maintenance doses after 4 weeks, while 21% remained on starting doses.
    3 context sentences
    Summary · context
    Adults with type 2 diabetes initiating GLP-1RAs between 1 March 2018 and 30 June 2023, with follow-up ≥1-year, were identified using the IQVIA Medical Research Data (IMRD) incorporating data from THIN, A Cegedim Database.
    Summary · context
    The absolute 1-year risk of discontinuation was estimated using the Aalen-Johansen estimator, while multivariable cause-specific Cox models assessed associations with patient characteristics.
    Summary · context
    Dosing trajectories were characterised across individual prescriptions during the first therapy year.
  6. 06HumanObservational studyOther

    Among subcutaneous/oral semaglutide initiators with T2DM, 21% remained on starting doses after 4 weeks.

    In plain wordsAmong semaglutide users with diabetes, 21% remained on starting doses after 4 weeks.

    Peptide
    Semaglutide
    Outcome
    Not applicableRemaining on starting doses
    Study

    n: not reported in source

    Outcome group
    Treatment adherence and retention · Pharmacology
    Studied dose
    Dose not stated · 4 weeksAs given in this study (human).

    Measurements

    Starting dose persistence
    21%
    subcutaneous/oral semaglutide

    Source sentences

    Summary
    Only 58% of subcutaneous/oral semaglutide initiators reached recommended maintenance doses after 4 weeks, while 21% remained on starting doses.
    3 context sentences
    Summary · context
    Adults with type 2 diabetes initiating GLP-1RAs between 1 March 2018 and 30 June 2023, with follow-up ≥1-year, were identified using the IQVIA Medical Research Data (IMRD) incorporating data from THIN, A Cegedim Database.
    Summary · context
    The absolute 1-year risk of discontinuation was estimated using the Aalen-Johansen estimator, while multivariable cause-specific Cox models assessed associations with patient characteristics.
    Summary · context
    Dosing trajectories were characterised across individual prescriptions during the first therapy year.
  7. 07HumanObservational studyOther

    In adults with T2DM, 44.0% of subcutaneous semaglutide prescriptions at prescription 10 were for 0.5 mg.

    In plain wordsIn adults with diabetes, 44.0% of injected semaglutide prescriptions at prescription 10 were for 0.5 mg.

    Peptide
    Semaglutide
    Outcome
    Not applicableDose distribution at prescription 10
    Study

    n: not reported in source

    Outcome group
    Treatment adherence and retention · Pharmacology
    Studied dose
    0.5 mg · subcutaneous · 1 yearAs given in this study (human).

    Measurements

    Dose proportion
    44%
    0.5 mg subcutaneous semaglutide

    Source sentences

    Summary
    At prescription 10, most common doses were 0.5/1 mg subcutaneous semaglutide (44.0%/48.6%), 7/14 mg oral semaglutide (50.2%/36.6%), and 0.75/1.5/3 mg dulaglutide (20.4%/71.5%/6.7%).
    3 context sentences
    Summary · context
    Adults with type 2 diabetes initiating GLP-1RAs between 1 March 2018 and 30 June 2023, with follow-up ≥1-year, were identified using the IQVIA Medical Research Data (IMRD) incorporating data from THIN, A Cegedim Database.
    Summary · context
    The absolute 1-year risk of discontinuation was estimated using the Aalen-Johansen estimator, while multivariable cause-specific Cox models assessed associations with patient characteristics.
    Summary · context
    Dosing trajectories were characterised across individual prescriptions during the first therapy year.
  8. 08HumanObservational studyOther

    In adults with T2DM, 48.6% of subcutaneous semaglutide prescriptions at prescription 10 were for 1 mg.

    In plain wordsIn adults with diabetes, 48.6% of injected semaglutide prescriptions at prescription 10 were for 1 mg.

    Peptide
    Semaglutide
    Outcome
    Not applicableDose distribution at prescription 10
    Study

    n: not reported in source

    Outcome group
    Treatment adherence and retention · Pharmacology
    Studied dose
    1 mg · subcutaneous · 1 yearAs given in this study (human).

    Measurements

    Dose proportion
    48.6%
    1 mg subcutaneous semaglutide

    Source sentences

    Summary
    At prescription 10, most common doses were 0.5/1 mg subcutaneous semaglutide (44.0%/48.6%), 7/14 mg oral semaglutide (50.2%/36.6%), and 0.75/1.5/3 mg dulaglutide (20.4%/71.5%/6.7%).
    3 context sentences
    Summary · context
    Adults with type 2 diabetes initiating GLP-1RAs between 1 March 2018 and 30 June 2023, with follow-up ≥1-year, were identified using the IQVIA Medical Research Data (IMRD) incorporating data from THIN, A Cegedim Database.
    Summary · context
    The absolute 1-year risk of discontinuation was estimated using the Aalen-Johansen estimator, while multivariable cause-specific Cox models assessed associations with patient characteristics.
    Summary · context
    Dosing trajectories were characterised across individual prescriptions during the first therapy year.
  9. 09HumanObservational studyOther

    In adults with T2DM, 50.2% of oral semaglutide prescriptions at prescription 10 were for 7 mg.

    In plain wordsIn adults with diabetes, 50.2% of oral semaglutide prescriptions at prescription 10 were for 7 mg.

    Peptide
    Semaglutide
    Outcome
    Not applicableDose distribution at prescription 10
    Study

    n: not reported in source

    Outcome group
    Treatment adherence and retention · Pharmacology
    Studied dose
    7 mg · oral · 1 yearAs given in this study (human).

    Measurements

    Dose proportion
    50.2%
    7 mg oral semaglutide

    Source sentences

    Summary
    At prescription 10, most common doses were 0.5/1 mg subcutaneous semaglutide (44.0%/48.6%), 7/14 mg oral semaglutide (50.2%/36.6%), and 0.75/1.5/3 mg dulaglutide (20.4%/71.5%/6.7%).
    3 context sentences
    Summary · context
    Adults with type 2 diabetes initiating GLP-1RAs between 1 March 2018 and 30 June 2023, with follow-up ≥1-year, were identified using the IQVIA Medical Research Data (IMRD) incorporating data from THIN, A Cegedim Database.
    Summary · context
    The absolute 1-year risk of discontinuation was estimated using the Aalen-Johansen estimator, while multivariable cause-specific Cox models assessed associations with patient characteristics.
    Summary · context
    Dosing trajectories were characterised across individual prescriptions during the first therapy year.
  10. 10HumanObservational studyOther

    In adults with T2DM, 36.6% of oral semaglutide prescriptions at prescription 10 were for 14 mg.

    In plain wordsIn adults with diabetes, 36.6% of oral semaglutide prescriptions at prescription 10 were for 14 mg.

    Peptide
    Semaglutide
    Outcome
    Not applicableDose distribution at prescription 10
    Study

    n: not reported in source

    Outcome group
    Treatment adherence and retention · Pharmacology
    Studied dose
    14 mg · oral · 1 yearAs given in this study (human).

    Measurements

    Dose proportion
    36.6%
    14 mg oral semaglutide

    Source sentences

    Summary
    At prescription 10, most common doses were 0.5/1 mg subcutaneous semaglutide (44.0%/48.6%), 7/14 mg oral semaglutide (50.2%/36.6%), and 0.75/1.5/3 mg dulaglutide (20.4%/71.5%/6.7%).
    3 context sentences
    Summary · context
    Adults with type 2 diabetes initiating GLP-1RAs between 1 March 2018 and 30 June 2023, with follow-up ≥1-year, were identified using the IQVIA Medical Research Data (IMRD) incorporating data from THIN, A Cegedim Database.
    Summary · context
    The absolute 1-year risk of discontinuation was estimated using the Aalen-Johansen estimator, while multivariable cause-specific Cox models assessed associations with patient characteristics.
    Summary · context
    Dosing trajectories were characterised across individual prescriptions during the first therapy year.
  11. 11HumanObservational studyOther

    In adults with T2DM, 20.4% of dulaglutide prescriptions at prescription 10 were for 0.75 mg.

    In plain wordsIn adults with diabetes, 20.4% of dulaglutide prescriptions at prescription 10 were for 0.75 mg.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableDose distribution at prescription 10
    Study

    n: not reported in source

    Outcome group
    Treatment adherence and retention · Pharmacology
    Studied dose
    0.75 mg · 1 yearAs given in this study (human).

    Measurements

    Dose proportion
    20.4%
    0.75 mg dulaglutide

    Source sentences

    Summary
    At prescription 10, most common doses were 0.5/1 mg subcutaneous semaglutide (44.0%/48.6%), 7/14 mg oral semaglutide (50.2%/36.6%), and 0.75/1.5/3 mg dulaglutide (20.4%/71.5%/6.7%).
    3 context sentences
    Summary · context
    Adults with type 2 diabetes initiating GLP-1RAs between 1 March 2018 and 30 June 2023, with follow-up ≥1-year, were identified using the IQVIA Medical Research Data (IMRD) incorporating data from THIN, A Cegedim Database.
    Summary · context
    The absolute 1-year risk of discontinuation was estimated using the Aalen-Johansen estimator, while multivariable cause-specific Cox models assessed associations with patient characteristics.
    Summary · context
    Dosing trajectories were characterised across individual prescriptions during the first therapy year.
  12. 12HumanObservational studyOther

    In adults with T2DM, 71.5% of dulaglutide prescriptions at prescription 10 were for 1.5 mg.

    In plain wordsIn adults with diabetes, 71.5% of dulaglutide prescriptions at prescription 10 were for 1.5 mg.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableDose distribution at prescription 10
    Study

    n: not reported in source

    Outcome group
    Treatment adherence and retention · Pharmacology
    Studied dose
    1.5 mg · 1 yearAs given in this study (human).

    Measurements

    Dose proportion
    71.5%
    1.5 mg dulaglutide

    Source sentences

    Summary
    At prescription 10, most common doses were 0.5/1 mg subcutaneous semaglutide (44.0%/48.6%), 7/14 mg oral semaglutide (50.2%/36.6%), and 0.75/1.5/3 mg dulaglutide (20.4%/71.5%/6.7%).
    3 context sentences
    Summary · context
    Adults with type 2 diabetes initiating GLP-1RAs between 1 March 2018 and 30 June 2023, with follow-up ≥1-year, were identified using the IQVIA Medical Research Data (IMRD) incorporating data from THIN, A Cegedim Database.
    Summary · context
    The absolute 1-year risk of discontinuation was estimated using the Aalen-Johansen estimator, while multivariable cause-specific Cox models assessed associations with patient characteristics.
    Summary · context
    Dosing trajectories were characterised across individual prescriptions during the first therapy year.
  13. 13HumanObservational studyOther

    In adults with T2DM, 6.7% of dulaglutide prescriptions at prescription 10 were for 3 mg.

    In plain wordsIn adults with diabetes, 6.7% of dulaglutide prescriptions at prescription 10 were for 3 mg.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableDose distribution at prescription 10
    Study

    n: not reported in source

    Outcome group
    Treatment adherence and retention · Pharmacology
    Studied dose
    3 mg · 1 yearAs given in this study (human).

    Measurements

    Dose proportion
    6.7%
    3 mg dulaglutide

    Source sentences

    Summary
    At prescription 10, most common doses were 0.5/1 mg subcutaneous semaglutide (44.0%/48.6%), 7/14 mg oral semaglutide (50.2%/36.6%), and 0.75/1.5/3 mg dulaglutide (20.4%/71.5%/6.7%).
    3 context sentences
    Summary · context
    Adults with type 2 diabetes initiating GLP-1RAs between 1 March 2018 and 30 June 2023, with follow-up ≥1-year, were identified using the IQVIA Medical Research Data (IMRD) incorporating data from THIN, A Cegedim Database.
    Summary · context
    The absolute 1-year risk of discontinuation was estimated using the Aalen-Johansen estimator, while multivariable cause-specific Cox models assessed associations with patient characteristics.
    Summary · context
    Dosing trajectories were characterised across individual prescriptions during the first therapy year.
  14. 14HumanObservational studyOther

    In adults with T2DM, higher BMI was linked to faster subcutaneous semaglutide escalation to 1 mg at prescription 5.

    In plain wordsIn adults with diabetes, higher BMI was linked to faster dose increases with injected semaglutide.

    Peptide
    Semaglutide
    Outcome
    IncreaseDose escalation by BMI
    Study

    n: not reported in source

    Comparator
    Lower BMI groups
    Outcome group
    Treatment adherence and retention · Pharmacology
    Studied dose
    Dose not stated · subcutaneous · 1 yearAs given in this study (human).

    Measurements

    Receiving 1 mg
    20.8%
    BMI <30 at prescription 5
    Receiving 1 mg
    25.9%
    BMI 30-<35 at prescription 5
    Receiving 1 mg
    33.2%
    BMI >=35 at prescription 5

    Source sentences

    Summary
    Faster dose escalation occurred with higher BMI and subcutaneous semaglutide (1 mg at prescription 5: 20.8%/25.9%/33.2% with BMI 2).
    3 context sentences
    Summary · context
    Adults with type 2 diabetes initiating GLP-1RAs between 1 March 2018 and 30 June 2023, with follow-up ≥1-year, were identified using the IQVIA Medical Research Data (IMRD) incorporating data from THIN, A Cegedim Database.
    Summary · context
    The absolute 1-year risk of discontinuation was estimated using the Aalen-Johansen estimator, while multivariable cause-specific Cox models assessed associations with patient characteristics.
    Summary · context
    Dosing trajectories were characterised across individual prescriptions during the first therapy year.

Studies that did not test the peptide alone4

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

  1. 15HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyOther

    Among GLP-1RA initiators including dulaglutide, discontinuation risk was higher without obesity than with obesity.

    In plain wordsAmong GLP-1 drug users including dulaglutide, treatment discontinuation was linked to lower BMI.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    IncreasePooled discontinuation risk by obesity
    Study

    n = 8,200

    Comparator
    Higher BMI groups
    Outcome group
    Treatment adherence and retention · Pharmacology

    Measurements

    Discontinuation risk
    41.1%
    all initiators
    Discontinuation risk
    49.2%
    BMI <30
    Discontinuation risk
    40.4%
    BMI 30-<35
    Discontinuation risk
    37.2%
    BMI >=35

    Source sentences

    Summary
    the 1-year discontinuation risk was 41.1% (95% CI 40.1-42.2), higher among those without obesity (BMI 2: 49.2%, 46.5-52.0) versus with BMI ≥30 kg/m2 (BMI 30-2: 40.4%/37.2%, 38.4-42.4/35.4-39.1).
    3 context sentences
    Summary · context
    Adults with type 2 diabetes initiating GLP-1RAs between 1 March 2018 and 30 June 2023, with follow-up ≥1-year, were identified using the IQVIA Medical Research Data (IMRD) incorporating data from THIN, A Cegedim Database.
    Summary · context
    The absolute 1-year risk of discontinuation was estimated using the Aalen-Johansen estimator, while multivariable cause-specific Cox models assessed associations with patient characteristics.
    Summary · context
    Dosing trajectories were characterised across individual prescriptions during the first therapy year.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  2. 16HumanNot a test of Semaglutide aloneObservational studyOther

    Among GLP-1RA initiators including semaglutide, discontinuation risk was higher without obesity than with obesity.

    In plain wordsAmong GLP-1 drug users including semaglutide, treatment discontinuation was linked to lower BMI.

    Peptide
    Semaglutide
    Outcome
    IncreasePooled discontinuation risk by obesity
    Study

    n = 8,200

    Comparator
    Higher BMI groups
    Outcome group
    Treatment adherence and retention · Pharmacology

    Measurements

    Discontinuation risk
    41.1%
    all initiators
    Discontinuation risk
    49.2%
    BMI <30
    Discontinuation risk
    40.4%
    BMI 30-<35
    Discontinuation risk
    37.2%
    BMI >=35

    Source sentences

    Summary
    the 1-year discontinuation risk was 41.1% (95% CI 40.1-42.2), higher among those without obesity (BMI 2: 49.2%, 46.5-52.0) versus with BMI ≥30 kg/m2 (BMI 30-2: 40.4%/37.2%, 38.4-42.4/35.4-39.1).
    3 context sentences
    Summary · context
    Adults with type 2 diabetes initiating GLP-1RAs between 1 March 2018 and 30 June 2023, with follow-up ≥1-year, were identified using the IQVIA Medical Research Data (IMRD) incorporating data from THIN, A Cegedim Database.
    Summary · context
    The absolute 1-year risk of discontinuation was estimated using the Aalen-Johansen estimator, while multivariable cause-specific Cox models assessed associations with patient characteristics.
    Summary · context
    Dosing trajectories were characterised across individual prescriptions during the first therapy year.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  3. 17HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyOther

    Among GLP-1RA users including dulaglutide, additional analyses such as CVD history showed no further heterogeneity.

    In plain wordsAmong GLP-1 drug users including dulaglutide, additional analyses showed no further variation, including by cardiovascular disease history.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    No significant changeHeterogeneity in additional analyses
    Study

    n: not reported in source

    Outcome group
    Treatment adherence and retention · Pharmacology

    Source sentences

    Summary
    Additional analyses (e.g., by CVD history) revealed no further heterogeneity.
    3 context sentences
    Summary · context
    Adults with type 2 diabetes initiating GLP-1RAs between 1 March 2018 and 30 June 2023, with follow-up ≥1-year, were identified using the IQVIA Medical Research Data (IMRD) incorporating data from THIN, A Cegedim Database.
    Summary · context
    The absolute 1-year risk of discontinuation was estimated using the Aalen-Johansen estimator, while multivariable cause-specific Cox models assessed associations with patient characteristics.
    Summary · context
    Dosing trajectories were characterised across individual prescriptions during the first therapy year.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  4. 18HumanNot a test of Semaglutide aloneObservational studyOther

    Among GLP-1RA users including semaglutide, additional analyses such as CVD history showed no further heterogeneity.

    In plain wordsAmong GLP-1 drug users including semaglutide, additional analyses showed no further variation, including by cardiovascular disease history.

    Peptide
    Semaglutide
    Outcome
    No significant changeHeterogeneity in additional analyses
    Study

    n: not reported in source

    Outcome group
    Treatment adherence and retention · Pharmacology

    Source sentences

    Summary
    Additional analyses (e.g., by CVD history) revealed no further heterogeneity.
    3 context sentences
    Summary · context
    Adults with type 2 diabetes initiating GLP-1RAs between 1 March 2018 and 30 June 2023, with follow-up ≥1-year, were identified using the IQVIA Medical Research Data (IMRD) incorporating data from THIN, A Cegedim Database.
    Summary · context
    The absolute 1-year risk of discontinuation was estimated using the Aalen-Johansen estimator, while multivariable cause-specific Cox models assessed associations with patient characteristics.
    Summary · context
    Dosing trajectories were characterised across individual prescriptions during the first therapy year.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 2

    21 Oct 2026, 18:59 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.